OSTX Earnings — OS Therapies Incorporated Post-ER Performance | BigEarnings
OSTX — OS Therapies Incorporated
XASE · Healthcare · Biotechnology
Price$2.14
Market Cap$95.3M
P/E—
52W Range$1.15 – $2.57
Next Earnings2026-08-17
About OS Therapies Incorporated
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
🤖 AI Earnings Analysis
Clinical-stage biotech raised **$XX million** via registered direct offering of 2.5M shares while missing EPS estimates by **$0.08**. Dilutive funding provides runway for osteosarcoma programs amid challenging development landscape.
